- Home
- MDGL vs BEP Comparison
MDGL vs BEP Comparison
Compare MDGL & BEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDGL
- BEP
- Stock Information
- Founded
- MDGL 2011
- BEP 1999
- Country
- MDGL United States
- BEP Canada
- Employees
- MDGL N/A
- BEP N/A
- Industry
- MDGL Biotechnology: Pharmaceutical Preparations
- BEP Electric Utilities: Central
- Sector
- MDGL Health Care
- BEP Utilities
- Exchange
- MDGL Nasdaq
- BEP Nasdaq
- Market Cap
- MDGL 7.4B
- BEP 6.5B
- IPO Year
- MDGL N/A
- BEP N/A
- Fundamental
- Price
- MDGL $308.44
- BEP $22.93
- Analyst Decision
- MDGL Buy
- BEP Strong Buy
- Analyst Count
- MDGL 14
- BEP 5
- Target Price
- MDGL $347.33
- BEP $31.60
- AVG Volume (30 Days)
- MDGL 355.8K
- BEP 597.9K
- Earning Date
- MDGL 10-31-2024
- BEP 01-31-2025
- Dividend Yield
- MDGL N/A
- BEP 6.19%
- EPS Growth
- MDGL N/A
- BEP N/A
- EPS
- MDGL N/A
- BEP N/A
- Revenue
- MDGL $76,813,000.00
- BEP $5,767,000,000.00
- Revenue This Year
- MDGL N/A
- BEP $17.92
- Revenue Next Year
- MDGL $194.49
- BEP $6.80
- P/E Ratio
- MDGL N/A
- BEP N/A
- Revenue Growth
- MDGL N/A
- BEP 17.43
- 52 Week Low
- MDGL $168.25
- BEP $19.92
- 52 Week High
- MDGL $368.29
- BEP $29.56
- Technical
- Relative Strength Index (RSI)
- MDGL 51.11
- BEP 32.83
- Support Level
- MDGL $289.80
- BEP $22.53
- Resistance Level
- MDGL $315.09
- BEP $24.21
- Average True Range (ATR)
- MDGL 12.44
- BEP 0.71
- MACD
- MDGL -4.11
- BEP -0.15
- Stochastic Oscillator
- MDGL 48.58
- BEP 18.87
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.
About BEP Brookfield Renewable Partners L.P.
Brookfield Renewable is a globally diversified, multitechnology owner and operator of clean energy assets. The company's portfolio consists of hydroelectric, wind, solar, and storage facilities in North America, South America, Europe, and Asia and totals over 20 gigawatts of installed capacity. Brookfield Renewable invests in assets directly, as well as with institutional partners, joint venture partners, and through other arrangements. The company offers two separate listings for investors: Brookfield Renewable Partners and Brookfield Renewable Corp.